MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Medtronic PLC (MDT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising growth potential in surgical robotics and diabetes management markets, its recent financial performance shows declining net income and EPS. Additionally, technical indicators do not suggest a clear upward trend, and Congress trading data shows a cautious stance with more selling activity. For now, holding the stock or waiting for a better entry point might be more prudent.
The MACD histogram is -0.494, below 0, and is negatively contracting, indicating bearish momentum. The RSI is at 39, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. Key support is at 95.951, and resistance is at 98.627. The stock is trading below the pivot level, suggesting limited upward momentum in the short term.
Medtronic's Hugo surgical robot, with FDA approval, has significant growth potential in the surgical robotics market.
The MiniMed Go Smart MDI system launch in Europe enhances its diabetes management portfolio.
Hedge funds are significantly increasing their holdings, indicating institutional confidence.
The company offers a 2.9% dividend yield, nearing Dividend King status.
Congress members have shown a cautious stance, with 4 recent sale transactions and no purchases.
Declining net income (-11.67% YoY) and EPS (-11.88% YoY) in Q3
Gross margin dropped by 2.47% YoY, indicating potential cost pressures.
Analysts have mixed ratings, with some lowering price targets and expressing concerns about 2027 sustainability.
In Q3 2026, Medtronic's revenue increased by 8.74% YoY to $9.017 billion, showing solid top-line growth. However, net income dropped by 11.67% YoY to $1.143 billion, and EPS declined by 11.88% to $0.89. Gross margin also fell by 2.47% YoY to 60%, indicating challenges in profitability.
Analysts have mixed views on Medtronic. Positive ratings include Mizuho's Outperform rating with a $125 price target and Barclays' Overweight rating with a $118 price target. However, JPMorgan, Baird, and Truist lowered their price targets to $100-$103, citing concerns about 2027 sustainability and modest financial performance. Overall, the sentiment is neutral to slightly positive but lacks strong consensus support.
